Cargando…
Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations
Baseline locomotion and behavioral traits in the common marmoset Parkinson's disease model were examined to provide basic information for preclinical evaluations of medical treatments. A single regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine at a cumulative dose of 5 mg/kg as the free b...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams and Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964884/ https://www.ncbi.nlm.nih.gov/pubmed/31625972 http://dx.doi.org/10.1097/FBP.0000000000000509 |
_version_ | 1783488541803675648 |
---|---|
author | Ando, Kiyoshi Inoue, Takashi Hikishima, Keigo Komaki, Yuji Kawai, Kenji Inoue, Ryo Nishime, Chiyoko Nishinaka, Eiko Urano, Koji Okano, Hideyuki |
author_facet | Ando, Kiyoshi Inoue, Takashi Hikishima, Keigo Komaki, Yuji Kawai, Kenji Inoue, Ryo Nishime, Chiyoko Nishinaka, Eiko Urano, Koji Okano, Hideyuki |
author_sort | Ando, Kiyoshi |
collection | PubMed |
description | Baseline locomotion and behavioral traits in the common marmoset Parkinson's disease model were examined to provide basic information for preclinical evaluations of medical treatments. A single regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine at a cumulative dose of 5 mg/kg as the free base over three consecutive days was administered subcutaneously to 10 marmosets. Data obtained from these marmosets were compared to pre-1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine levels or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine free marmosets. After the single regimen, reduced daily locomotion, a measure of immobility (a primary sign of Parkinsonism), was observed for more than a year. A moving tremor was also observed by visual inspection during this period. When apomorphine (0.13 mg/kg, s.c.) was administered, either right or left circling behavior was observed in a cylindrical chamber in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine marmosets, suggestive of unequal neural damage between the two brain hemispheres to different extents. MRI revealed that T1 relaxation time in the right substantia nigra correlated with right circling in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine marmosets. Histology was supportive of dopaminergic neural loss in the striatum. These results increase our understanding of the utility and limitations of the Parkinson's disease model in marmosets with a single 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine regimen, and provide reference data for efficacious preclinical evaluations. |
format | Online Article Text |
id | pubmed-6964884 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams and Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-69648842020-02-03 Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations Ando, Kiyoshi Inoue, Takashi Hikishima, Keigo Komaki, Yuji Kawai, Kenji Inoue, Ryo Nishime, Chiyoko Nishinaka, Eiko Urano, Koji Okano, Hideyuki Behav Pharmacol Research Reports Baseline locomotion and behavioral traits in the common marmoset Parkinson's disease model were examined to provide basic information for preclinical evaluations of medical treatments. A single regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine at a cumulative dose of 5 mg/kg as the free base over three consecutive days was administered subcutaneously to 10 marmosets. Data obtained from these marmosets were compared to pre-1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine levels or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine free marmosets. After the single regimen, reduced daily locomotion, a measure of immobility (a primary sign of Parkinsonism), was observed for more than a year. A moving tremor was also observed by visual inspection during this period. When apomorphine (0.13 mg/kg, s.c.) was administered, either right or left circling behavior was observed in a cylindrical chamber in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine marmosets, suggestive of unequal neural damage between the two brain hemispheres to different extents. MRI revealed that T1 relaxation time in the right substantia nigra correlated with right circling in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine marmosets. Histology was supportive of dopaminergic neural loss in the striatum. These results increase our understanding of the utility and limitations of the Parkinson's disease model in marmosets with a single 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine regimen, and provide reference data for efficacious preclinical evaluations. Lippincott Williams and Wilkins 2020-02 2020-01-10 /pmc/articles/PMC6964884/ /pubmed/31625972 http://dx.doi.org/10.1097/FBP.0000000000000509 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Research Reports Ando, Kiyoshi Inoue, Takashi Hikishima, Keigo Komaki, Yuji Kawai, Kenji Inoue, Ryo Nishime, Chiyoko Nishinaka, Eiko Urano, Koji Okano, Hideyuki Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations |
title | Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations |
title_full | Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations |
title_fullStr | Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations |
title_full_unstemmed | Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations |
title_short | Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations |
title_sort | measurement of baseline locomotion and other behavioral traits in a common marmoset model of parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations |
topic | Research Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964884/ https://www.ncbi.nlm.nih.gov/pubmed/31625972 http://dx.doi.org/10.1097/FBP.0000000000000509 |
work_keys_str_mv | AT andokiyoshi measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations AT inouetakashi measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations AT hikishimakeigo measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations AT komakiyuji measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations AT kawaikenji measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations AT inoueryo measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations AT nishimechiyoko measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations AT nishinakaeiko measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations AT uranokoji measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations AT okanohideyuki measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations |